QUICK ANSWER
Coverage Overview
Short answer: Cigna coverage for Zepbound varies by plan. Some employer-sponsored plans cover it with prior authorization (and some add Evernorth's optional $200/month cost cap), while many individual plans exclude weight loss medications and basic Medicare Part D coverage excludes them for weight loss (the separate Medicare GLP-1 Bridge, which runs outside Part D, can cover the Zepbound KwikPen, with conditions).
Is Zepbound covered by Cigna?
Many Cigna plans do not cover Zepbound for weight loss. Coverage depends on whether your employer's plan includes weight-loss drugs; Cigna's policy says your benefit plan document overrides its coverage policy.[12] Some plans may offer coverage under specific conditions:
- Some employer-sponsored commercial plans cover Zepbound with prior authorization, sometimes with a $200/month out-of-pocket cap
- Many individual / ACA marketplace plans exclude weight loss medications
- Medicare Advantage plans formerly sold by Cigna (Cigna sold its Medicare Advantage and Part D businesses to Health Care Service Corporation (HCSC) on March 19, 2025) don't cover Zepbound for weight loss under their basic Part D coverage (federal law excludes drugs used for weight loss), but members with eligible drug coverage can use the Medicare GLP-1 Bridge, which runs outside Part D, for the Zepbound KwikPen ($50 per monthly fill, with prior authorization and other conditions)
Who this guide is for
Cigna members exploring Zepbound coverage through employer-sponsored commercial plans, ACA marketplace plans, Medicare Advantage plans formerly sold by Cigna, or Express Scripts-administered pharmacy benefits.
Why Cigna Coverage Varies by Employer and Plan
Cigna coverage differences are driven by who controls your benefits (employer vs insurer), how the plan is funded (fully insured vs self-funded), and your medical indication. This is why two Cigna members can receive very different coverage decisions, even within the same company.
- Large employers can customize their formularies and may add GLP-1 coverage
- Some plans now include the $200/month Evernorth cost cap
- Express Scripts is Cigna's pharmacy benefit manager; your ID card shows who runs your pharmacy benefit
To determine your exact coverage, check directly with Cigna. If you're denied, you still have options.
What to Know If You're Denied
Independent analyses suggest that 65% or more of properly documented appeals are overturned for commercial insurance[7]—yet only about 1 in 10 patients ever appeal. Whether you've already been denied or are preparing for prior authorization, you still have options.
Denied already? See your appeal options →
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
Coverage Outlook for 2026
Express Scripts’ 2026 formulary excludes Zepbound KwikPens and vials; Zepbound single-dose pens, Wegovy and Foundayo are preferred, for employer plans that cover obesity medications.[13] The Evernorth cost cap is $200/month cap (only if your employer adds it). For Medicare, the GLP-1 Bridge is live (July 1, 2026 – December 31, 2027).
Last updated October 6, 2026 · Key facts verified October 5, 2026 · Full page reviewed October 5, 2026
Cigna Plans & Express Scripts
Unlike BCBS (which operates as 33 independent companies), Cigna operates nationally through Express Scripts, its pharmacy benefit manager (PBM).
Coverage is primarily determined by:
- Your Plan Type — large employer / small employer / individual / Medicare
- Express Scripts Formulary — whether your employer's plan includes GLP-1 coverage
Coverage varies by employer plan design, not by state. Call to check your coverage →
Pro tip: Calling can allow you to get more helpful information that isn't always available online.
Things to Keep in Mind
- Prior Auth is required — even when listed. Getting your full coverage details makes this a smoother process.
- If not covered — there are still different "exception" paths and options to consider.
- If denied, file an appeal — 65%+ of properly documented appeals succeed for commercial insurance.[7]
- Other conditions can unlock coverage — such as sleep apnea and different comorbidities.
If this feels overwhelming, you're not alone. Take it one step at a time, starting with asking your plan what it covers.
But coverage isn't the full story. Express Scripts administers most Cigna pharmacy benefits, and your plan type matters more than you might think.
See how Express Scripts affects your coverage →CIGNA'S PHARMACY BENEFIT MANAGER
Does Express Scripts Cover Zepbound?
Express Scripts is Cigna's pharmacy benefit manager (PBM). It administers the prescription drug formulary, prior authorization rules, and pharmacy claims processing for Cigna plans that use it.
Whether Express Scripts "covers" Zepbound depends entirely on your underlying Cigna plan:
| Your Plan Type | Express Scripts Shows | What It Means |
|---|---|---|
| Employer w/ GLP-1 coverage | "Covered with PA" | Your employer opted to cover it; PA required |
| Employer w/o GLP-1 coverage | "Not covered" | Your employer didn't add GLP-1 coverage |
| Individual / Marketplace | "Not covered" in many plans | Many individual plans exclude weight loss drugs; check your plan's drug list |
| Former Cigna Medicare (Part D), now HCSC | Not by the plan; Medicare GLP-1 Bridge: $50 per monthly fill (with conditions) | Federal law excludes weight loss drugs from basic Part D coverage; the Bridge covers the Zepbound KwikPen outside Part D, with prior authorization |
How to Check Your Express Scripts Coverage
- Log into Express Scripts at express-scripts.com or the Express Scripts app
- Search for "Zepbound" in the drug lookup tool
- Review the result: "covered with prior authorization," "not covered," or "excluded"
- For confirmation, call the Member Services number on your Cigna ID card
Key Point
Express Scripts publishes the formulary (for example, which Zepbound forms are preferred or excluded), but whether weight-loss drugs are covered at all is set by your plan. All the coverage criteria, prior authorization rules, and appeal steps on this page apply both to Cigna and to Express Scripts as the PBM.
Cigna's $200/Month Cap Program
In 2025, Cigna's Evernorth division announced a program that caps out-of-pocket costs for Zepbound and Wegovy at $200 per month on employer-sponsored plans that add it.[15] Evernorth says its EncircleRx program has more than 9 million enrolled lives and has saved health plans $200 million since 2024.[15]
- $200/month maximum for Zepbound and Wegovy
- Simplified prior authorization designed to speed up access[15]
- Available only if your employer opts in — not automatic for all Cigna plans
- EnGuide Pharmacy — home delivery option, staffed by clinicians who specialize in GLP-1s[15]
- EnReachRx — Evernorth's high-touch patient support model for GLP-1 prescriptions[15]
Questions to ask Cigna or HR:
- "Is my plan enrolled in the Evernorth $200/month GLP-1 cost cap?"
- "If so, does it apply to Zepbound specifically?"
- "Do I have access to EnGuide home delivery or EnReachRx pharmacist support?"
Express Scripts answers depend on your plan type.
See how plan type affects coverage →PLAN + EMPLOYER RULESHow Plan Type Affects Your Coverage
How Plan Type Affects Your Coverage
Your Zepbound coverage is shaped by your plan type and employer decisions:
- Your Plan Type — who controls your benefits (your employer, Cigna, government)
- Employer Benefit Design — whether your employer added GLP-1 coverage
Think of it this way:
Cigna sets default formularies, but employers can customize them. Large employers may have more flexibility than small ones.
That's why two people with Cigna — even at the same company — can get different coverage if they chose different plan options.
Cigna Plan Types and Potential Coverage
| Your Plan Type | Chance of Coverage | Why |
|---|---|---|
| Large Employer (1,000+ employees) | Varies widely | In KFF's 2025 survey, 43% of firms with 5,000+ workers, and 16% of firms with 200–999 workers (2025) covered GLP-1s for weight loss[18]; $200/mo cap on some plans |
| Small Employer (may be fully insured) | Excluded in many plans | Fully-insured plans less likely to include GLP-1s |
| Individual / ACA Marketplace | Excluded in many plans | Many individual plans exclude weight loss drugs |
| Former Cigna Medicare Advantage (now HCSC) | Through the Medicare GLP-1 Bridge | Basic Part D coverage excludes weight-loss drugs; MA-PD members can use the Bridge, which runs outside Part D (Zepbound KwikPen only, prior authorization required) |
Legend: Possible coverage · Likely excluded · Depends on employer plan design
More Details / Next Steps (Based on Plan Type)
Large Employer Plans — May Offer the Best Chance
Many large companies pay for healthcare themselves (this is called "self-funded"). Cigna just handles administration through Express Scripts.
That means your employer — not Cigna — decides whether drugs like Zepbound are covered.
Small Employer Plans — Follow Cigna's Standard Rules
Small employers that buy a fully insured Cigna plan choose from Cigna's standard plan options, so whether weight-loss drugs are covered depends on what those options include.
Individual / ACA Marketplace Plans — Many Exclude Weight-Loss Drugs
If you bought your plan through Healthcare.gov or directly from Cigna, it's a standard, non-customized plan. Many of these plans exclude weight-loss drugs.
- Coverage through the sleep apnea indication (or Mounjaro, if you have type 2 diabetes)
- Switching plans during open enrollment
- Self-pay options
Cigna Medicare Advantage — Not by the Plan; Medicare GLP-1 Bridge Instead
If you're on Medicare, federal law excludes drugs used for weight loss from basic Part D coverage, and that includes the drug coverage in Medicare Advantage plans formerly sold by Cigna (Cigna sold its Medicare Advantage and Part D businesses to Health Care Service Corporation (HCSC) on March 19, 2025). However, the separate Medicare GLP-1 Bridge, a temporary CMS program that runs outside the Part D benefit, is live (July 1, 2026 – December 31, 2027) for members with eligible Part D drug coverage who meet CMS's criteria and whose prescriber gets prior authorization.[19]
- Type 2 diabetes: Mounjaro may be covered under Part D, subject to the plan's formulary, prior authorization and exceptions process
- Moderate-to-severe obstructive sleep apnea (OSA): Zepbound (FDA-approved for OSA in adults with obesity) may be covered under Part D, subject to the plan's formulary, prior authorization and exceptions process
- $50 per monthly fill copay for eligible beneficiaries
- Eligibility: Age 18+ and BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled high blood pressure or CKD stage 3a+; or BMI ≥27 with prediabetes, a prior heart attack or stroke, or symptomatic PAD
- Covers Wegovy (injection and pill), Foundayo, and the Zepbound KwikPen ; Zepbound vials and single-dose pens are not covered
- Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization
- Not eligible: Not eligible if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), or if your Part D plan paid for a GLP-1 for you at any time in 2026. People with moderate-to-severe OSA use the Part D route above instead
The separate BALANCE Model in Medicare Part D is Delayed, with no new start date.
FIND YOUR PATHBased on Your Situation
Based on Your Situation
Now that you understand coverage patterns, here's what to do next:
PA Denied?
Your plan covers Zepbound, but your prior authorization was rejected.
- You have 180 days to file an appeal (check your denial letter)
Plan Excludes It?
Zepbound isn't on your formulary (your plan's list of covered drugs) at all.
Exclusion options → Still Checking?
Haven't applied yet or want to understand your options first.
- Use our call script to verify with Cigna
- Check the 2026 outlook for coverage trends
Not Sure Which Applies? Check your denial letter.
- "Not medically necessary" or "step therapy required" = PA denial (you can appeal)
- "Excluded benefit" or "not covered" = plan exclusion (different strategy needed)
WHAT'S COMING
Cigna Coverage Outlook for 2026
Generally Stable Coverage for 2026
Unlike some BCBS affiliates that are reducing GLP-1 coverage, Express Scripts' 2026 formulary keeps Zepbound single-dose pens as a preferred option for plans that cover obesity medications (KwikPens and vials are excluded). The Evernorth cost cap is $200/month cap (only if your employer adds it).
What's Confirmed for 2026
- Zepbound pens on 2026 formulary: Express Scripts’ 2026 formulary excludes Zepbound KwikPens and vials; Zepbound single-dose pens, Wegovy and Foundayo are preferred[13]
- $200/month cap (optional): The Evernorth cost-cap benefit announced in May 2025 applies only if your employer adds it
- Medicare GLP-1 Bridge (live): The Medicare GLP-1 Bridge runs July 1, 2026 – December 31, 2027 with $50 per monthly fill copays for eligible beneficiaries (Age 18+ and BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled high blood pressure or CKD stage 3a+; or BMI ≥27 with prediabetes, a prior heart attack or stroke, or symptomatic PAD), with prior authorization; Zepbound only as the KwikPen[19]
What This Means for You
- Check your specific plan: Coverage depends on your employer's benefit design—don't assume
- During open enrollment: Ask HR if your employer is adding the $200/month cap or GLP-1 coverage
- Self-funded employers: Large employers can add or modify GLP-1 coverage at renewal
- Consider alternatives: If you have Type 2 diabetes, Mounjaro (same active ingredient) may be covered
CALL YOUR INSURANCEVerify Your Specific Coverage
Verify Your Specific Coverage
Even though it takes a little more time, we recommend calling so you can speak with a person who may have more information than the online directory or PDF formulary listing.
Call Script for Cigna
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Zepbound (tirzepatide) covered on my plan's formulary for weight management?
- What tier is it on?
- Is prior authorization required?
- What are the coverage criteria—BMI, comorbidities, step therapy?
- Does my plan have the $200/month Evernorth cost cap for GLP-1s?
- Can you send me the coverage policy in writing?"
Pro tip: Always request coverage criteria in writing. Verbal confirmations aren't binding, and having documentation helps if you need to appeal later.
Cigna Contact Information
| Department | Phone Number | Use For |
|---|---|---|
| Member Services | Number on ID card | Coverage questions, benefits |
| Cigna Customer Service (24/7) | 1-800-244-6224 | General coverage, claims and benefits questions; for PA status and appeals, the number on your ID card is best[6] |
COMMON CRITERIA FOR ZEPBOUNDPrior Authorization Requirements
Prior Authorization Requirements
When Cigna does cover Zepbound, prior authorization is required. Key criteria from Cigna's Zepbound coverage policy (IP0816, effective September 1, 2026):[12]
- Age 18+ and BMI ≥30 (or ≥27 with a weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, sleep apnea or cardiovascular disease)
- At least 3 months of behavioral modification and dietary restriction
- No concurrent GLP-1 use — can't take Zepbound with Ozempic/Wegovy
- Approval and renewal: first approval 8 months; renewal for 1 year needs ≥5% weight loss from baseline. No drug step is required by the policy[12]
Cigna Decision Timelines
- Standard review: for employer plans covered by federal (ERISA) claims rules, those rules allow up to 15 days
- Expedited review: under the same rules, up to 72 hours (if medically urgent)
Quantity Limits (Updated 2025-2026)
Cigna enforces quantity limits based on dosage strength:[3]
- Most strengths: 4 pens per 28 days at retail (12 per 84 days by home delivery)
- Re-initiation/re-titration: a one-time override for 4 extra pens is available for some strengths (2.5, 7.5 and 12.5 mg) if you need to restart or re-titrate
Renewal Requirement — Don't Miss This
Cigna's Zepbound policy requires you to have lost at least 5% of your starting body weight to renew after the first 8 months approval. (A 10% weight-loss requirement applies only to the sleep-apnea route, after a year of therapy.)[12] If you don't meet these thresholds, your renewal may be denied — even if the medication is working for you in other ways.
For complete documentation checklists and PA preparation: Zepbound Prior Authorization Guide →
YOUR PLAN COVERS ITIf Your PA Was Denied
If Your PA Was Denied
Your plan covers Zepbound, but the prior authorization was rejected. This is actually good news — 65%+ of properly documented appeals succeed for commercial insurance.[7]
Why Fight for Coverage?
Win your appeal → pay as little as $25/month with Lilly's savings card. Without coverage, you'd pay $299–$449/month via LillyDirect (list price about $1,086/month). The card saves up to $100 per 1-month fill, so $25 applies when your cost before the card is $125 or less.
Common PA Denial Reasons
- Medical necessity not met → Medical Necessity Guide
- Step therapy required → Step Therapy Guide
- BMI criteria not met → BMI Criteria Guide
- Missing lifestyle documentation → Lifestyle Documentation Guide
Cigna Appeal Basics
- Deadline: 180 days from denial to file internal appeal (check your letter)
- Contact: the number on your ID card, or Cigna Customer Service: 1-800-244-6224
- Tip: Submit via fax to get instant confirmation of receipt
For complete appeal strategies: Zepbound Appeals Guide → | External Review Process
Need help with your Cigna appeal? Start your free appeal review →
DIFFERENT STRATEGY NEEDEDIf Your Plan Excludes Zepbound
If Your Plan Excludes Zepbound
Zepbound isn't on your plan's drug list at all. Standard appeals won't work for a plan exclusion, but you have other options.
Your Options
- Request a formulary exception — your doctor can argue medical necessity → If Zepbound is not covered by your insurance
- Try the OSA pathway — if you have sleep apnea, some plans that exclude weight loss still cover Zepbound for OSA
→ Sleep Apnea Coverage Guide - Talk to HR — if you have employer insurance, ask if they can add GLP-1 coverage at renewal
- Switch plans during open enrollment — verify GLP-1 coverage in writing before switching
- Explore self-pay options — savings cards, LillyDirect ($299–$449/month; TrumpRx.gov, launched Feb 2026, lists the same prices), and patient assistance may reduce costs → Zepbound Cost Guide
- Consider oral options — Foundayo (Eli Lilly's new oral GLP-1, FDA approved April 1, 2026) may have different coverage
OSA Coverage May Be Different
Sleep Apnea Indication — Worth Exploring
Zepbound was FDA-approved to treat obstructive sleep apnea (OSA) in adults with obesity.[1] Some Cigna plans that don't cover Zepbound for weight loss may cover it for OSA.
If you have OSA symptoms (snoring, daytime sleepiness, witnessed breathing pauses), ask your doctor about a sleep study. An AHI (Apnea-Hypopnea Index) score ≥15 could open coverage pathways.
Have an Employer Plan? Talk to HR
If you have insurance through your employer, your HR/Benefits department may be able to help:
- Self-funded employers (typically larger companies) can modify coverage—they're not bound by standard Cigna rules
- Ask HR to advocate for adding GLP-1 coverage at the next plan renewal
- Request the $200/month Evernorth cap be added if your plan doesn't have it
CIGNA ZEPBOUND COVERAGE
Frequently Asked Questions
It depends on your Cigna plan. Express Scripts is Cigna's pharmacy benefit manager (PBM). It publishes the formulary (on its 2026 National Preferred Formulary, Zepbound single-dose pens are preferred and KwikPens and vials are excluded), but whether weight-loss drugs are covered at all depends on your Cigna plan design. Employer plans with GLP-1 coverage will show it as covered with prior authorization; plans without GLP-1 coverage will show "not covered."
Some Cigna plans do, but many do not. Coverage depends on your specific plan type. Employer-sponsored commercial plans are most likely to include coverage, especially large self-funded employers. Individual marketplace plans typically exclude weight loss medications; Medicare Advantage plans can't cover them, but members with drug coverage can use the Medicare GLP-1 Bridge. In 2025, Cigna's Evernorth introduced a $200/month out-of-pocket cap that applies only if your employer adds it.
Cigna's Zepbound policy (IP0816) requires: age 18+, BMI ≥30 or ≥27 with a weight-related condition (such as hypertension, type 2 diabetes, dyslipidemia, OSA, or cardiovascular disease), at least 3 months of behavioral modification and dietary restriction, and no other GLP-1 medication at the same time. The first approval lasts 8 months; to renew for 1 year you must show at least 5% weight loss from baseline. (The sleep-apnea route requires 10% weight loss to renew after a year.)
On Express Scripts' 2026 National Preferred Formulary, Zepbound single-dose pens are a preferred option (KwikPens and vials are excluded); your copay tier depends on your plan. Plans with the optional $200/month Evernorth cap limit the monthly cost. Prior authorization is required.
You have 180 days from the denial notice to file an internal appeal (check your letter). Request the denial in writing with the specific reason, then submit an appeal the way your denial letter describes (for example, through myCigna or by mail). Include supporting documentation like a Letter of Medical Necessity and clinical evidence. Your doctor can also request a peer-to-peer review. If the internal appeal fails, you can request a binding external review within 4 months (check your state).
Not through the plan itself, but yes through the Medicare GLP-1 Bridge. (Cigna's Medicare Advantage and Part D plans now belong to HCSC: Cigna sold its Medicare Advantage and Part D businesses to Health Care Service Corporation (HCSC) on March 19, 2025.) Federal law excludes drugs used for weight loss from basic Part D coverage. However, the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), a temporary CMS program that runs outside the Part D benefit, covers the Zepbound KwikPen (not single-dose pens or vials) with $50 per monthly fill copays for beneficiaries with eligible Part D coverage who meet CMS's criteria (Age 18+ and BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled high blood pressure or CKD stage 3a+; or BMI ≥27 with prediabetes, a prior heart attack or stroke, or symptomatic PAD) and whose prescriber gets prior authorization. Separately, if you have moderate-to-severe obstructive sleep apnea (OSA), Zepbound may be covered under Part D for that FDA-approved use, subject to the plan's formulary, prior authorization and exceptions process (people with moderate-to-severe OSA can't use the Bridge).
In May 2025, Cigna's Evernorth division launched a program that caps patient out-of-pocket costs at $200/month for Zepbound and Wegovy. Evernorth says its EncircleRx program has more than 9 million enrolled lives and has saved health plans $200 million since 2024. Related options include EnGuide Pharmacy (home delivery staffed by GLP-1 clinicians) and EnReachRx (a high-touch patient support model). However, it's only available on employer plans that opt into the program—ask your HR department or call Cigna to check if your plan participates.
YOUR PATH FORWARD
What's Next
Zepbound Coverage: Other Major Insurers
See how other insurers compare on Zepbound coverage:
- UnitedHealthcare — Depends on your employer’s plan; PA required where covered
- Blue Cross Blue Shield — Varies by Blue company; some (e.g., Massachusetts) dropped weight-loss coverage in 2026
- Aetna — Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize) (Aetna's PBM); customized plans vary
- Anthem Blue Cross — Separate policies from other BCBS affiliates
- Humana — Humana no longer sells employer-group commercial medical plans (exit completed in 2025); Medicare drug plan members can use the Medicare GLP-1 Bridge
Other GLP-1 Medications at Cigna
Cigna's coverage varies by medication. Compare your options:
References
- FDA. (2024). "FDA Approves First Medication for Obstructive Sleep Apnea." https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
- Cigna Healthcare. (2025). "2025 Prescription Drug List Changes." https://www.cigna.com/static/www-cigna-com/docs/2025-prescription-drug-list-changes.pdf
- Cigna Healthcare. (2025). "Zepbound Drug Quantity Management Policy." https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_840_coveragepositioncriteria_zepbound_dqm_per_days.pdf
- Cigna Healthcare. (2025). "2025 Formulary Standard List of Covered Drugs." https://www.cigna.com/static/www-cigna-com/docs/medicare/plans-services/2025/formulary-group-standard.pdf
- Cigna Healthcare. (2025). "2025 Cigna Healthcare Formulary Assurance." https://www.cigna.com/static/www-cigna-com/docs/medicare/plans-services/2025/formulary-assurance.pdf
- Cigna Healthcare. "Contact Us." https://www.cigna.com/contact-us/
- American Medical Association / KFF Analysis. (2024). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" Note: The 80%+ figure reflects Medicare Advantage data; commercial insurance appeal success rates are typically 65%+ based on industry analyses. https://www.ama-assn.org/practice-management/prior-authorization/over-80-prior-auth-appeals-succeed-why-aren-t-there-more
- Jastreboff AM, et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. SURMOUNT-1 trial. https://pubmed.ncbi.nlm.nih.gov/35658024/
- U.S. Government Accountability Office. (2011). "Private Health Insurance: Data on Application and Coverage Denials." GAO-11-268. https://www.gao.gov/assets/gao-11-268.pdf
- Drug Topics. (2025). "Evernorth Benefit Option Will Cap Wegovy, Zepbound Monthly Cost at $200." May 22, 2025. https://www.drugtopics.com/view/evernorth-benefit-option-will-cap-wegovy-zepbound-monthly-cost-at-200
- HealthCare.gov. "External Review." https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
- Cigna Healthcare. (2026). "Weight Loss – Glucagon-Like Peptide-1 Agonists – Zepbound," Drug Coverage Policy IP0816 (effective 09/01/2026). https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0816_coveragepositioncriteria_weight_loss_zepbound.pdf
- Express Scripts. (2026). "2026 National Preferred Formulary Exclusions" (EXCL-NPF-26, 10/01/2026). https://www.express-scripts.com/pdf/formulary/NPF_Preferred_Formulary_Exclusions2026.pdf
- American Hospital Association. (2024). "Payer Denial Tactics—How to Confront a $20 Billion Problem." https://www.aha.org/aha-center-health-innovation-market-scan/2024-04-02-payer-denial-tactics-how-confront-20-billion-problem
- Evernorth Health Services. (2025). "Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month." May 21, 2025. https://www.evernorth.com/articles/evernorth-launches-new-benefit-option-drives-lower-net-cost-weight-loss-medicines
- Healthcare Dive. (2025). "Cigna doubles down on GLP-1 support programs with 2 new launches." May 2, 2025. EncircleRx covers 9 million patients, has saved insurers $200 million. EnReachRx launched Q1 2025. https://www.healthcaredive.com/news/cigna-evernorth-glp1-support-programs-enreachrx-enguide-q1-2025/746967/
- Fierce Healthcare. (2025). "New Evernorth program to cap out-of-pocket costs for Wegovy, Zepbound at $200." May 21, 2025. Includes EnGuide home delivery option. https://www.fiercehealthcare.com/payers/new-evernorth-program-cap-out-pocket-costs-wegovy-zepound-200
- KFF. (2025). "2025 Employer Health Benefits Survey." https://www.kff.org/health-costs/2025-employer-health-benefits-survey/
- CMS. "Medicare GLP-1 Bridge." https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge; The Cigna Group. (March 19, 2025). Sale of Medicare businesses to HCSC (SEC 8-K). sec.gov
- Express Scripts. (2025). "2026 Express Scripts National Preferred Formulary." https://www.express-scripts.com/art/open_enrollment/Preferred_Members_FormularyRxGuide.pdf
- Honest Care. (2025). "GLP-1 Patient Access Report — Q3/Q4 2025." https://www.findhonestcare.com/insights/glp1-coverage-2025/
Last updated October 6, 2026 · Key facts verified October 5, 2026 · Full page reviewed October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.